CFTR and cystic fibrosis: Finally, an open-label clinical trial evaluated effects of oral losartan (50 mg twice daily for 14 weeks) on mucociliary and cough clearance (MCC/CC) in pwCF off CFTR modulators as they have a need for novel therapies (NCT03435939).<h4>Results</h4>In sheep, oral losartan (50 mg twice daily for 4 days) did not achieve ASL levels expected to improve CF-associated mucociliary dysfunction based on our previous data.